BA3182

Nov. 13, 2025: BioAtla, Inc. (NASDAQ: BCAB) reported Q3 2025 results and provided program updates across Ozuriftamab vedotin (Oz-V; CAB-ROR2-ADC), BA3182 (CAB-EpCAM x CAB-CD3 T-cell engager), and mecbotamab vedotin (Mec-V; CAB-AXL-ADC), and noted it is in advanced stages of finalizing a strategic transaction with a potential partner targeted for completion by year end.

Oz-V (Fast Track; NCT05271604): Following an end-of-Phase 2 FDA Type B meeting, the company said it achieved FDA alignment on the planned Phase 3 registrational trial design (dosing, comparator, endpoints) in 2L+ oropharyngeal squamous cell carcinoma (OPSCC). The randomized Phase 3 will use dual primary endpoints of overall response rate and overall survival, with a path that could support accelerated approval followed by full approval. BioAtla is preparing to initiate the Phase 3 study and said it is on track to advance with a strategic partner in early 2026.

BA3182 (NCT05808634): Preliminary Phase 1 dose-escalation data (ESMO 2025) showed prolonged tumor control at higher doses; a confirmed partial response at 0.6 mg was ongoing >6 months in intrahepatic cholangiocarcinoma. Two cytokine release syndrome cases were reported as of Sept. 10, 2025. Readout is expected in 1H 2026; expansion readouts later in 2026.

Mec-V (NCT03425279): Phase 2 soft tissue sarcoma data (SITC 2025; 44 evaluable patients) reported median OS 21.5 months and 12-month OS 73%; no treatment-related deaths as of March 25, 2025 cut-off.

CAB-Nectin4-TCE (BA3362): Context Therapeutics triggered and paid a $2M milestone (Oct. 2025) under the license agreement.